Is Compounded Microdose GLP-1 Still Legal in 2026?

Almost every microdose of GLP-1 in the United States comes from a compounding pharmacy, not from an FDA-approved pen or pill. So the legal status of compounded GLP-1 is the legal status of microdosing — and in 2026 that status is narrower than it has ever been. The short answer: compounding under the patient-specific (503A) pathway is still legal in principle, but the broad, low-cost supply that made microdosing cheap and easy is being shut down. Here is exactly where the line sits, with the primary sources.

First, why compounded GLP-1 existed at all

US law lets pharmacies compound a drug that is otherwise a commercial product when that product is in a declared shortage. Both semaglutide and tirzepatide spent much of 2022–2024 on the FDA drug-shortage list, and that shortage status is what opened the floodgates for compounded — and therefore microdosed — GLP-1. The clinical literature is explicit that microdosing "emerged amid GLP-1 compounding restrictions" as a workaround built on patient anecdote rather than tested regimens¹.

That foundation has now been removed. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025. Once a shortage is declared over, the legal basis that allowed mass compounding of "essentially a copy" of the branded drug goes away — and a phased wind-down for compounders began.

The 2026 development: the 503B door is being shut for good

There are two kinds of compounders, and the distinction is the whole story.

• •503B outsourcing facilities make compounded product in bulk, without a prescription for a named patient, and ship it to clinics and telehealth platforms. They may only compound from a "bulk drug substance" when that substance is either on the FDA's official 503B bulks list or covered by an active shortage.
• •503A pharmacies compound for one identified patient at a time, against an individual prescription, under state board of pharmacy oversight.

The big 2026 news targets the first group. In a notice published in the Federal Register on May 1, 2026, the FDA proposed to leave semaglutide, tirzepatide, and liraglutide off the 503B bulks list, concluding there is no clinical need for outsourcing facilities to compound them from bulk now that FDA-approved versions are available. The public comment period runs through June 29, 2026. If finalized, this removes the last standing pathway for large-scale, prescription-free compounding of these GLP-1s.

The agency's stated reason is partly a safety one. As of early 2025 it had logged more than 455 adverse-event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide — many involving dosing errors by patients self-administering from multidose vials, some requiring hospitalization. That is the same DIY-measurement risk that makes microdosing specifically hazardous, which we cover in is compounded / microdosed GLP-1 safe.

So is microdosing still legal? The 503A carve-out

Here is the nuance that headlines miss. The 503B proposal does not by itself outlaw the 503A patient-specific pathway. A 503A pharmacy can still, in principle, compound semaglutide or tirzepatide against an individual prescription. That carve-out is what keeps microdosing narrowly alive in 2026.

But two constraints make that pathway far smaller than the shortage-era free-for-all:

1. 1.The "essentially a copy" rule. With the shortages over, a 503A pharmacy generally cannot compound something that is essentially a copy of a commercially available approved drug. Compounding is meant for a documented, patient-specific clinical reason — an allergy to an inactive ingredient, a needed dosage form the manufacturer does not make — not "I want the same drug, cheaper, at a lower dose." The FDA has said it found no basis to conclude such patient-specific attributes broadly exist for these three GLP-1s.
2. 2.A microdose is not, by itself, a recognized clinical need. Wanting a sub-therapeutic dose for tolerability or cost is not, on its own, the kind of documented clinical difference the law contemplates. A genuine 503A prescription has to rest on a specific clinical justification for that patient.

The honest framing: compounded microdose GLP-1 is not flatly "illegal" in 2026, but the easy, telehealth-at-scale supply most people used is being switched off, and what remains is a narrow, prescription-by-prescription, clinically-justified channel — not a casual one.

What this means in practice

If you are currently microdosing compounded GLP-1, expect three things over 2026: bulk-compounding sources from outsourcing facilities drying up, telehealth programs that relied on them pivoting or pausing, and any continued compounding shifting toward documented patient-specific need. None of this is legal advice, and none of it is a substitute for talking to a clinician and a licensed pharmacist about your specific situation.

If your compounded supply is discontinued, there are now FDA-approved oral options that did not exist a year ago — we walk through what continued maintenance can look like in microdosing GLP-1 for maintenance and how to come off safely in how to taper off GLP-1. For the underlying economics that drove people to compounding in the first place, see what does microdosing GLP-1 cost, and for how people obtained it, how to get microdosing tirzepatide.

For the full evidence picture on whether microdosing does anything at the doses people actually use, read our pillar, microdosing GLP-1 — what the evidence actually shows, or compare programs on the GLP-1 microdose rankings hub. This is a fast-moving regulatory situation; verify current status against the FDA's own notices before acting.